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Abstract Pompe disease is a rare lysosomal glycogen
storage disorder characterized by deficiency of acid !-
glucosidase enzyme (GAA) and caused by mutations in
the GAA gene. Infantile-type Pompe disease is a multi-
organ disorder presenting with cardiomyopathy, hypoto-
nia, and muscular weakness, which is usually fatal.
Enzyme replacement therapy (ERT) with recombinant
human GAA (rhGAA) has recently been shown to be
effective and subsequently yielded promising results in
cross-reactive immunologic material (CRIM)-positive
patients. CRIM-negative patients showed a limited re-
sponse to ERT and died or were ventilator dependant.
Over a period of 44 months, we monitored cognitive and
motor development, behavior, auditory function, and brain
imaging of a CRIM-negative infantile Pompe disease
patient on rhGAA and monoclonal anti-immunoglobulin
E (anti-IgE) antibody (omalizumab) treatment due to
severe allergic reaction. Cardiorespiratory and skeletal
muscle response was significant, with almost normal
motor development. Cognitive development—in particular,
speech and language—deviated increasingly from normal
age-appropriate development and was markedly delayed at
44 months, unexplained by moderate sensorineural hearing
impairment. Brain magnetic resonance imaging (MRI) at 18,
30, and 44 months of age revealed symmetrical signal
alteration of the deep white matter. Titer values of IgG
antibodies to rhGAA always remained <1:800. The potential
role of omalizumab in immune modulation remains to be
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elucidated; however, this is the first report presenting a
ventilator-free survival of a CRIM-negative patient beyond
the age of 36 months. The central nervous system (CNS)
findings are hypothesized to be part of a yet not fully
described CNS phenotype in treated patients with longer
survival.
Abbreviations
ERT enzyme replacement therapy
MRI magnetic resonance imaging
CNS central nervous system
GAA acid α-glucosidase
Introduction
Pompe disease (glycogen storage disease type II, MIM
#232300) is a rare, progressive, metabolic neuromuscular
disorder resulting from lysosomal acid !-glucosidase (GAA)
deficiency (Hirschhorn and Reuser 2001) inherited as an
autosomal recessive disease. The phenotype of Pompe
disease is heterogeneous and primarily characterized by
accumulation of glycogen in skeletal and cardiac muscle
associated with progressive skeletal muscle weakness in all
variants of the disease and by rapidly progressive hypertro-
phic cardiomyopathy and early death at about the age of
1 year in patients with the severe infantile variant (Hirschhorn
and Reuser 2001; Kishnani and Howell 2004; Kishnani et al.
2006a). Glycogen accumulation, however, has also been well
documented in central (CNS) and peripheral (PNS) nervous
systems (Gambetti et al. 1971; Mancall et al. 1965; Martin et
al. 1973; Sakurai et al. 1974), also leading to cochlear
dysfunction with subsequent hearing loss (Kamphoven et al.
2004). In patients with clinical symptoms suggestive for
Pompe disease, diagnosis is based on marked reduction of
GAA activity in purified peripheral blood lymphocytes
(Winchester et al. 2008). In general, GAA enzyme activity
in fibroblasts of <1% of that of normal controls is associated
with rapid disease progression, as seen in the infantile form,
whereas in the late onset forms, GAA activity ranges from
2% to 40% of normal controls, and disease progression is
much slower. Incidence data are limited, with reports ranging
from 1:300,000 to 1:14,000 livebirths (Hirschhorn and
Reuser 2001). A recent study, however, testing for Pompe
disease by newborn screening resulted in a prevalence of
1:33,333 in Taiwan (Chien et al. 2008). In all disease
variants, morbitity and mortality is high (Kishnani and
Howell 2004), and for decades, treatment was limited to
supportive care. It was only in 2006 that enzyme replacement
therapy (ERT) with recombinant human GAA (rhGAA) was
approved for commercial use in North America and Europe
and yielded promising results, particularly in patients with
infantile Pompe disease.
Early intervention with ERT is essential to reverse
cardiomyopathy and to halt motor disease progression. In
addition, it was hypothesized from the first clinical trials
that the presence or absence of cross-reactive immunological
material (CRIM) may affect prognosis (Amalfitano et al.
2001). CRIM-negative patients are completely unable to
form any precursor form of native enzyme, whereas patients
who are able to produce some precursor form of abnormal-
or normal-size native enzyme are CRIM-positive. Kishnani
et al. reported that CRIM-negative status predicted reduced
overall survival and invasive ventilator-free survival and
poorer motor development in ERT-treated infants with
Pompe disease (Kishnani et al. 2010). The effect of CRIM
status was hypothesized to be mediated by antibody response
to exogenous protein (Kishnani et al. 2007; Kishnani et al.
2010; Kishnani et al. 2006b). Induction of immune
modulation to eliminate antibodies in a CRIM-negative
patient was first reported through intravenous administration
of gamma globulin, anti-CD20 monoclonal antibody (ritux-
imab), and methotrexate (Mendelsohn et al. 2009) and
proved to be a promising approach to overcome poor
prognosis in CRIM-negative patients (Kishnani et al. 2010).
Here we report on a 44-month follow-up of a CRIM-
negative patient with infantile Pompe disease started on
ERT early, subsequently including anti-immunoglobulin
E (anti-IgE) antibody (omalizumab) treatment from the
age of 6 months due to severe IgE-mediated allergic
reactions to Myozyme. To the best of our knowledge,
this is the first report of a CRIM-negative patient on ERT
and monoclonal anti-IgE antibody. In the patient de-
scribed in this report, application of omalizumab was
ensued by immunomodulatory effects, as indicated by
sustained low titers of rhGAA-IgG; such unforeseen
effects of anti-IgE antibodies beyond neutralization of
IgE might deserve further investigation.
Case report
This now 44-month-old child of consanguineous Turkish
parents (first-degree cousins) was born after an uneventful
pregnancy. The mother was raised in Switzerland and
speaks German fluently; the father immigrated to Switzerland
at the age of 6 years and speaks and understands German. At
the age of 4 weeks, a heart murmur was noted at a routine
checkup and further investigations showed a hypertrophic
cardiomyopathy. Neurological examination revealed mild
axial, facial, and proximal weakness. Pompe disease was
suspected and confirmed by the absence of detectable serum
GAA activity in leukocytes and fibroblasts and a homozygous
mutation (c.1157insA) in the GAA gene; both parents are
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carriers for this mutation. Our patient tested CRIM-negative
(determined in cultured fibroblasts by a qualitative Western
blot assay prior to ERT; Genzyme, Laboratory, Westborough,
MA, USA). At the age of 8 weeks, ERT was started with
Myozyme® at a recommended dose of 20 mg/kg every
2 weeks for 3 months. Subsequently, the dose and frequency
of ERT had to be changed to 10 mg/kg weekly due to type III
allergic reactions; in addition, pretreatment with intravenously
applied corticosteroid and antihistaminic drugs was
begun, combined with a decreased infusion rate. Due to
persistent, severe life-threatening allergic reactions that
were not controllable with corticosteroids, antihistaminic
drugs, or decreased infusion rate, the regime was
optimized by adding omalizumab, a recombinant mono-
clonal antibody against IgE, at the age of 6 months. A
scratch skin test for Myozyme tested positive as well as
specific for Myozyme IgE hypersensitivity in a blood
sample (Genzyme). One year later, ERT intervals could
be extended to 14 mg/kg every 10 days and the
antiallergic treatment was successfully weaned with the
exception of omalizumab. Recombinant human GAA IgG
antibody titers were measured routinely every 4–5 months
and were always <1:800 (Table 1).
Response to treatment
Auditory function, cognitive and motor milestones, and
behavior were evaluated at 12-month intervals. The
progress of myelination was investigated by brain magnetic
resonance imaging (MRI). Cardiac function was monitored
Table 1 Response to enzyme replacement therapy (ERT)
At diagnosis 6 months on ERT 12-18 months
on ERT
30 months on ERT 44 months on ERT
Cardiac involvement
LVM g/m2 (n 42-95) 165 87 83 55 50
EF in % 48 52 55
Muscle weakness Sits Walks, climbs Runs, jumps, no
Gowers
Runs, jumps, no
Gowers
Proximal weakness M4 Months 4 Months 4-5 Months 4-5 Months 4-5
Facial and axial weakness Mild Months 3 Month 3 Months 3+ Months 3+
Cognitive development Age
appropriate
Griffith-Test age at
8 months
Griffith test at 18 m: Bayley test at age
32 months
SONER test at age
44 months
Locomotor 7 months Locomotor 16.5 m DA 22 months/DQ
70-75
DA 35 months/DQ
70-75
Eye and hand
8 months
Eye and hand
15.5 m
Nonverbal best item
26 m
Nonverbal best item
39 months
Hearing/language
14.5 m
Very short attention
span
Very short attention
span
Personal-social
16 m
No spoken words 1 spoken word
Performance 17 m Behavioural
problems
Behavioural
problems
Hearing
Otoacoustic emissions Failed
Auditory brainstem response
(thresholds dB)
80-90 bB
Behavioral audiometry high
frequencies
40 dB 40 dB 40 dB
Behavioral audiometry low
frequencies
60–70 dB 60–70 dB 60–70 dB
Hearing aids + +
Myozyme antibody testing
IgG Negative Negative Positive Positive Positive
Titer N/A N/A 1:400 1:400 1:400
LVM left ventricular mass measured by echocardiography, EF ejection fraction calculated by cardiac magnetic resonance imaging (MRI), DA
developmental age, DQ developmental quotient, N/A not available
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by echocardiography every 4 months and in addition by a
cardiac MRI at diagnosis and at the age of 33 and
44 months, respectively (Table 1).
Cardiac Initially, there was a severe concentric left ventricular
hypertrophy with a septum thickness on echocardiography of
9 mm (norm <6 mm) and a left ventricular mass (LVM) on
MRI of 162 g/m2 (norm 84 g/m2). Ventricular size and
systolic function were normal. At the age of 2 1/2 years,
myocardial hypertrophy was resolved. At the age of 3 1/
2 years, left ventricular end-diastolic volume was 68 ml/m2,
right ventricular end-diastolic volume 59 ml/m2, and LVM
was 50 g/m2 on MRI.
Respiratory No respiratory involvement was detectable by
yearly polysomnography, and no respiratory insufficiency
occurred during two episodes of bacterial pneumonia.
Muscle weakness Gross motor development and muscle
strength was almost normal, except for facial and neck
flexor muscles. At the age of 44 months, she had some
fatigability and ataxia.
Cognitive development The patient was only 5 weeks old at
diagnosis and was age appropriate on the Griffith Scale. After
6 months of ERT, there was no significant delay in the
locomotor and eye and hand subtests of the Griffith scale,
although the girl was difficult to test at that age because of
relevant allergic reactions and side effects of the antihista-
minic medication; at age 18 months, there was marked delay
in speech and language development but also delay in fine-
motor tasks and social behavior in the Griffith test. At the age
of 32 months, her overall developmental age was 22 months
in the Bayley test. In addition, she had a markedly reduced
attention span, behavioral problems such as aggressiveness
and repetitive behavior, and delays in expressive language and
speech development. Nonverbal development test SON-R
revealed a developmental age of 35 months at the chronolog-
ical age of 44 months; delays in expressive language and
speech development had not improved significantly when
compared with the age of 32 months.
Hearing The patient failed newborn hearing screening with
otoacoustic emissions, but clinically, she responded to
sounds. At 8 months of age re-evaluation by auditory
brainstem response (ABR) showed hearing thresholds on
both ears of 80–90 dB, and she responded as type B at the
time on tympanometry. After improvement of the middle
ear situation by paracentesis on both ears, behavioral
audiometry revealed that a hearing loss of 40 dB in the
low frequencies and 60–70 dB in the high frequencies
remained. In the following months, at the age of 26 months,
hearing aids were fitted that were well tolerated, and speech
and language therapy as well as orofacial therapy was
initiated. In free-field audiometry, the thresholds with
hearing aids were measured at 20–25 dB. During therapy
sessions, prompt reactions also to sounds with low intensity
were observed. Despite weekly auditory–verbal, speech,
and language therapy and regularly checking the fitting of
the hearing aids, the expressive language development
*
*
a
b
c
Fig. 1 Brain magnetic resonance imaging (MRI) on enzyme
replacement therapy (ERT) on follow-up showing white matter
changes appearing at the age of 20 months compared with MRI at
diagnosis. At the age of diagnosis (a), T-1 axial with normal age-
appropriate images showing normal myelination. At the age of
20 months (b): on the left, axial T-2 image; on the right, coronal
fast low-angle inversion recovery (FLAIR) image. Changes in white
matter, sparing U fibers (*): MRI at 32 months (c): on the left, axial T-
2 image; on the right, coronal FLAIR image. In comparison with b,
increased white matter signal intensity (*)
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remain delayed, in both Turkish and German, and articu-
lation is still difficult and limited to some vowels.
Brain imaging Before initiation of ERT, myelination was
age appropriate. Yearly MRI at age 1 1/2, 2 1/2, and 3 1/
2 years showed signal alterations in the white matter on T2
and fast low-angle inversion recovery (FLAIR) images with
sparing of U fibres. Myelination had progressed appropri-
ately. In the repeat scan at age 2 1/2 and 3 1/2 years,
respectively, signal alterations on FLAIR images and T2
markedly progressed (Fig. 1).
Discussion
We report almost normal motor milestones and normal-
ization of cardiac function in a CRIM-negative infantile
Pompe disease patient up to the age of 44 months.
Despite an excellent response of skeletal and cardiac
muscle, we noted progressive white matter changes on
MRI associated with a delay in cognitive, speech and
language development, as well as hearing loss and
behavior impairment.
Very little is known about the long-term cognitive
development of patients with infantile Pompe disease
independent of rhGAA CRIM status. Furthermore, there
are only a few reports on brain imaging in infants with
classic Pompe disease. This may be attributed to the early
mortality usually observed in untreated patients, the lack of
close monitoring OF CNS parameters due to the historical
endpoints chosen to prove the efficacy of ERT (Amalfitano
et al. 2001; Kishnani et al. 2006b, 2007; Klinge et al. 2005;
Van den Hout et al. 2001, 2004), or to difficulties of
cognitive testing and the risk of sedation for MRI in
patients on ERT who may still have significant respiratory
muscle weakness and/or cardiomyopathy. Furthermore, it
also became evident that not all patients responded equally
well to ERT regarding motor development, and it has been
shown that this is dependent on CRIM status and
hypothesized to be directly mediated by antibody response
to ERT (Kishnani et al. 2010).
The motor development of our CRIM-negative patient
was only slightly late; however, acquisition of motor
milestones was within normal limits and gain of motor
milestones is continuing. Muscle weakness significantly
improved over the course on ERT, predominantly being
limited to facial and neck flexor muscles; however,
cognitive testing using Griffith and Bayley scales and
SON-R indicated a deviation from age-appropriate devel-
opment; speech and language development were markedly
delayed, and behavioral issues were noted. Behavior
impairment in Pompe disease was only reported in a mouse
model (Sidman et al. 2008).
Only recently has it been reported that overall language
delay in infantile Pompe patients on ERT is common, with
a high risk of speech disorder caused by velopharyngeal
dysfunction and deficits in the orofacial mechanism;
however, overall language delays tended to improve or
remain stable over time (Muller et al. 2009). In addition,
hearing loss in Pompe disease is known; it is thought to be
caused by glycogen storage in the organ of Corti (Kamphoven
et al. 2004). Despite hearing aids for >12 months in our
patient, speech and language therapy, as well as orofacial
stimulation therapy, we did not note any improvement over
the period of time. At the age of 44 months, our patient did
not speak any words and had a nasal voice. Testing showed
that nonverbal skills were better compared with verbal.
Audiology assessment showed a moderate hearing loss but
not severe enough to explain all the language developmental
problems. There is no family history of cognitive or speech
problems; both parents have high school certificates and
speak German and Turkish fluently.
BrainMRI in our patient clearly reflects brain involvement,
particularly in the white matter. We speculate that these MRI
findings might explain the cognitive and most likely the
behavioral impairment; there is no evidence for a disorder
other than Pompe disease resulting in white matter changes,
although this might be a possibility in the context of
consanguinity. Little is known about possible side effects of
omalizumab; however, current data do not show evidence for
white matter changes in a small group of treated patients.
It has been clearly shown in the literature, however, that
untreated Pompe disease may also present with CNS
involvement. Several early and also more recent studies
(Burrow et al. 2010; Chen et al. 2004; Crome et al. 1963;
Engel et al. 1973; Gambetti et al. 1971; Lee et al. 1996;
Mancall et al. 1965; Martin et al. 1973) point to
abnormalities in the CNS and PNS, leading to a slowly
progressive neurodegenerative process. Chien et al.
reported myelination delay on MRI in five patients started
on ERT later than 5.5 months of age (Chien et al. 2006).
However, initial brain MRI was performed late, all but one
patient had significant motor developmental delays, and no
information regarding CRIM status, speech and language
development, or hearing was provided.
Due to severe allergic reaction with positive testing for
anti-Myozyme IgE, a recombinant monoclonal antibody
against IgE (omalizumab) was added to the regime for our
patient. Interestingly, anti-rhGAA IgG antibody titers
remained low (1:400) during the entire follow-up period
despite the CRIM-negative status. Anti-rhGAA IgG anti-
body titers are generally reported higher in CRIM-negative
patients (median peak titers 1:204,800) comparedwith CRIM-
positive patients (median peak titers 1:1,800) (Kishnani et al.
2010). We hypothesize that the monoclonal anti-IgE anti-
body used in this patient did not only halt further allergic
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reactions but unexpectedly might have also played an
important role as an immune modulator and thereby may
have contributed to the favorable motor outcome. We
consider this to be an interesting and important observation.
Although the underlying immunological mechanism is not
understood and the observation is based on a single case, we
suggest that omalizumab may be of benefit for patients with
IgE-mediated allergic reaction. Only long-term studies on a
larger patient population will help clarify a possible role and
the risk–benefit profile of this biological agent.
To the best of our knowledge our report describes for the
first time continuous motor milestones gain in a CRIM-
negative infantile Pompe disease patient on ERT over the
course of 44 months. However, the progressive white
matter changes on MRI associated with a delay in cognitive
development highlights the importance of close neurological
follow-up in treated patients with Pompe disease.
The significance of nervous system involvement in longer
survival in infantile Pompe disease patients is far from clear.
Further studies to confirm and extend these findings are
necessary, as they might have major implications regarding
the management and long-term prognosis, in particular for
CRIM-negative infantile Pompe disease patients on ERT. The
findings of possible CNS involvement despite ERT, however,
opens up the field for ethical discussions concerning the early
start of ERT and newborn screening for Pompe disease, as
well as on the emerging controversial debate about the cost-
effectiveness of ERT in lysosomal storage disorders.
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